EcoDrugPlus

Serpin Peptidase Inhibitor, Clade C (Antithrombin), Member 1

Ensembl ID : ENSEEEG00000015359
Gene Symbol: SERPINC1
4 Cross references
202 Possible Orthologues:

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSEEEG00000018966
Gene Symbol: SIGMAR1
4 Cross references
206 Possible Orthologues:

Sirtuin 1

Ensembl ID : ENSEEEG00000016808
Gene Symbol: SIRT1
4 Cross references
159 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSEEEG00000014079
Gene Symbol: SMO
4 Cross references
204 Possible Orthologues:

Sodium Channel, Voltage Gated, Type V-Like, Alpha B

Ensembl ID : ENSEEEG00000023749
Gene Symbol: SCN5LAB
1 Cross references
263 Possible Orthologues:

Sodium Channel, Voltage Gated, Type Viii, Alpha Subunit A

Ensembl ID : ENSEEEG00000004707
Gene Symbol: SCN8AA
4 Cross references
263 Possible Orthologues:

Sodium Channel, Voltage Gated, Type Viii, Alpha Subunit B

Ensembl ID : ENSEEEG00000010886
Gene Symbol: SCN8AB
4 Cross references
263 Possible Orthologues:

Sodium Channel, Voltage Gated, Type Xii, Alpha A

Ensembl ID : ENSEEEG00000008071
Gene Symbol: SCN12AA
4 Cross references
245 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSEEEG00000011156
Gene Symbol: SCN4A
4 Cross references
188 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-1

Ensembl ID : ENSEEEG00000001193
Gene Symbol: LOC113582621
4 Cross references
289 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-1-Like

Ensembl ID : ENSEEEG00000009365
Gene Symbol: LOC113582622
2 Cross references
298 Possible Orthologues:

Solute Carrier Family 18 Member 2

Ensembl ID : ENSEEEG00000021766
Gene Symbol: SLC18A2
2 Cross references
224 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).